Eris Lifesciences Limited has successfully completed its strategic acquisition of Swiss Parenterals Limited, transforming the subsidiary into a wholly-owned entity through a preferential share allotment completed on January 16, 2026. The pharmaceutical company's Executive Committee approved the allotment of equity shares in exchange for the remaining 30% stake in Swiss Parenterals.

Share Allotment Details

The Executive Committee of Eris Lifesciences' Board approved the allotment of significant equity shares to complete the acquisition:

The allotment was made on a preferential basis through private placement to Mr. Naishadh Shah in exchange for his 16,74,493 equity shares of Swiss Parenterals Limited, representing the remaining 30% stake in the subsidiary.

Capital Structure Impact

The share allotment has resulted in changes to Eris Lifesciences' capital structure:

Regulatory Compliance and Approvals

The transaction was executed following comprehensive regulatory compliance. The company received in-principle approval from both NSE and BSE on January 9, 2026, for the preferential issue. The process began with the board meeting held on November 24, 2025, followed by shareholder approval through postal ballot on December 24, 2025.

The allotment complies with provisions of the Companies Act, 2013, SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The newly allotted shares will rank pari-passu with existing equity shares, subject to lock-in restrictions under SEBI ICDR Regulations.

Strategic Implications

With the completion of this acquisition, Swiss Parenterals Limited has become a wholly-owned subsidiary of Eris Lifesciences. This strategic move provides the company with enhanced control over Swiss Parenterals' operations and potential operational synergies. The subscription shares will be listed on NSE and BSE upon receipt of relevant listing approvals and will be subject to lock-in provisions as specified under Chapter V of the SEBI ICDR Regulations.

Eris Lifesciences , a prominent player in the pharmaceuticals sector, has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The company's Board of Directors approved these results in a meeting held on November 12, 2025.

Financial Performance

For the quarter ended September 30, 2025 (Q2 FY26), Eris Lifesciences reported the following key financial metrics:

The company demonstrated strong growth across all major financial indicators. Notably, the net profit saw a substantial increase compared to the same quarter in the previous year.

Operational Highlights

• The Operating Profit Margin (OPM) improved to 36.2%, showing a significant increase of 40.36% compared to the same period last year.
• Other income for the quarter stood at ₹22.70 crore, representing a 336.54% increase year-over-year.
• The company's expenses rose by 8.70% to ₹362.30 crore, which is notably lower than the revenue growth rate, indicating improved operational efficiency.

Board Approvals and Corporate Actions

In addition to the financial results, the Board of Directors made several key decisions:

1. Director Reappointments:

   • Mr. Krishnakumar Vaidyanathan has been recommended for reappointment as Whole Time Director for a 5-year term from September 1, 2026, to August 31, 2031.
   • Ms. Kalpana Unadkat has been recommended for reappointment as Independent Director for a 5-year term from January 5, 2026, to January 4, 2031.

2. Employee Stock Option Scheme: The company issued 50,985 ordinary shares under its Employee Stock Option Scheme 2021 during the half-year period. This action has increased the paid-up share capital to ₹13.62 crore.

Business Segment

Eris Lifesciences continues to operate primarily in the pharmaceuticals business segment. The financial performance, coupled with strategic board decisions, may influence the company's operations in the coming years.

The reappointment of key directors suggests a focus on maintaining leadership continuity, which may contribute to the company's long-term strategic planning and execution.